Li, Lin
Sujan, Ayesha C.
Butwicka, Agnieszka
Chang, Zheng
Cortese, Samuele
Quinn, Patrick
Viktorin, Alexander
Öberg, A. Sara
D’Onofrio, Brian M. http://orcid.org/0000-0002-5248-7434
Larsson, Henrik
Funding for this research was provided by:
National Institute on Drug Abuse (R00DA040727, R01DA048042)
Vetenskapsrådet (2018-02599, 2018-02679)
Hjärnfonden (FO2018-0273)
Article History
First Online: 24 April 2020
Compliance with Ethical Standards
:
: Research reported in this publication was supported by the Swedish Research Council (no. 2018-02599 to Larsson and no. 2018-02679 to D’Onofrio), the Swedish Brain Foundation (Viktorin and no. FO2018-0273 to Larsson) and the National Institute on Drug Abuse of the National Institutes of Health under award number R00DA040727 (Quinn) and R01DA048042 (D’Onofrio, Quinn, Oberg). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
: HL has served as a speaker for Evolan Pharma and Shire and has received research grants from Shire, all outside the submitted work. SC has received honoraria and reimbursement of travel and accommodation expenses for lectures from the nonprofit associations Association for Child and Adolescent Central Health, Canadian ADHD Alliance Resource (CADDRA), and BAP and from Healthcare Convention for educational activity on ADHD. BD has received reimbursement of travel and accommodation expenses for CADDRA and Children and Adults with Attention-Deficit/Hyperactivity Disorder. LL, ACS, AB, ZC, PQ, AV, and ASÖ have no conflicts of interest that are directly relevant to the content of this article.